| Autor: |
Radka SF; Ribozyme Pharmaceuticals, Inc., Boulder, CO 80301, USA. radkas@rpi.com, Pasko C, Haeberli P, Beigelman L |
| Jazyk: |
angličtina |
| Zdroj: |
Analytical biochemistry [Anal Biochem] 2002 Aug 01; Vol. 307 (1), pp. 40-6. |
| DOI: |
10.1016/s0003-2697(02)00017-9 |
| Abstrakt: |
Ribozymes are catalytically active RNA molecules that cleave other RNA molecules in a sequence-specific fashion, with significant turnover. The successful design and synthesis of ribozymes with modifications to increase their stability in biological fluids, while maintaining catalytic activity, has been instrumental in moving this technology from the laboratory into clinical trials. With the entry of ribozymes into the clinical setting, the need has arisen for reagents and/or assays to detect these drugs in tissues. We have developed a monoclonal antibody to the 2(')-deoxy-2(')-C-allyl uridine modification present in our synthetic hammerhead ribozymes. The monoclonal antibody, termed CA1USR, is a murine IgG1(k), whose epitope appears to involve both the 2(')-C-allyl modification, and the uridine base. Use of CA1USR for immunohistochemical detection of ribozymes in the tissues of mice which were administered two structurally different ribozymes has demonstrated its utility as a reagent for in vivo localization of ribozymes containing the 2(')-C-allyl uridine modification. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
Full Text from ScienceDirect